April Losers (JNJ, account down 0.74%)4th trade in April is NYSE:JNJ .
Holding period is 68 days (1/26/23-4/4/23).
Account is down 0.74%.
Total return in April is -0.05%
JNJB34 trade ideas
Johnson & Johnson share outlook before the earningsShares in Johnson & Johnson (symbol ‘JNJ’) have been trading in a bearish momentum throughout the whole first quarter of 2023 before correcting to the upside in recent sessions. The company is expected to report its earnings for the fiscal quarter ending March 2023 on Tuesday 18th of April before market open. The consensus EPS is HKEX:2 ,50 compared to the result for the same quarter last year of HKEX:2 ,67.
‘Johnson & Johnson has been paying dividends since 1972 and is one of the very few companies to do that for such a long period of time. This proves that investors buying this share are in for the long term and with a payout ratio of more than 60% and a dividend yield of more than 2.70% also proves the commitment of the company towards its shareholders.‘ said Antreas Themistokleous, an analyst at Exness.’
On the technical side the price has been trading in a downward movement throughout the whole of the first quarter of the year but it has rebounded significantly in the recent sessions with the price making back almost 50% of the losses incurred in the first 3 months. The price is currently trading outside the Bollinger bands indicating great volatility in the market. The HKEX:166 level was a strong technical resistance area since it consists of the 50% of the daily Fibonacci retracement level and also the 100 day moving average.
With the Stochastic oscillator recording overbought levels and with the strong technical resistance still in play we might see some minor correction to the downside prior to the earnings release. If this is the case then we might see some support around the HKEX:157 price area which consists of the crossing of the 50 day moving average on the 23.6% of the Fibonacci retracement level.
Index investing vs individual stocks investingI picked on random a popular US pharma stock , J&J which was in the news recently for being fined 9.8 billion dollars and compare it with the US stock index , SPX 500 over a rough 20 years period.
So, say you are 30 years old back then and you put the same amount of money, $10,000 into each of these assets.
20 years later, the stock you bought, J&J would yield you an estimate of 250% growth , that is from 10,000 it becomes 25,000. This of course excludes dividends income to simplify things.
On the other hand, your 10,000 in the index, SPX500 would yield you 430% returns or from 10,000 to 43,000. This is an additional gain of 18,000 more than if you had picked up individual stock on your own.
Of course, there are plenty of stocks that could yield you triple to quadruple digit returns over the same time frame which I did not cover here. My point is picking up individual stocks would require more research and homework on your own, understanding the industry, company's financial performance, economic moat, projection into the future, etc. Would anyone have thought a 163 years old bank like Credit Suisse would suffer its fate today ? I seriously doubt so.....
There is a great margin of safety in investing in the index as it is a basket of stocks and those that fails to meet its requirements would be replaced by another company. And that takes the load off your mind to do the due diligence.
It all depends on your capital, risk appetite , personality, objectives of investing, time frame, etc in deciding which asset class to go to. Some prefer stability and peaceful night sleep and less hassle while others enjoy the roller coaster ride and adrenaline rush of seeing the stock performed better than the index. To each his own, no right or wrong, really.
You can also place half your capital, 5000 into the stock and 5000 into the index. That will give you a total return of 30,500 which is very good too.
I wish you all the best in your investing journey. Enjoy the ride!
JNJ STRONG BUY *****JNJ broke it's downtrend recently and bounced off strong support of $150, moving avergaes are crossing up we are trading below the cloud so plenty of resistance at $158 and $166,. I would buy and ADD
3/21 Watchlist + NotesSPY - We were slightly bullish on SPY if you saw yesterdays list. SPY finished green around 1% which is what we expected, but we made another inside day today putting SPY in a 2-1-1 pattern on the daily. I am still expecting us to push higher tomorrow, but I have a feeling it will be a tricky day of price action with FOMC on wednesday. Overall slightly bullish once again, but not banking on it.
Watchlist + Bias:
JNJ - 3-1 daily / 2-1 weekly: Neutral
GOOG - 2-1 Daily: Neutral
MRK - 2-1 Daily: Neutral
HD - 2-1 Daily: Neutral
LLY - 2-1 Daily: Slightly Bullish
MMM - 2-1 Daily: Neutral
Main Watch:
JNJ - We are in a very interesting spot with JNJ currently. Weekly chart is in an active 2-1 and overall is bearish because of the current weekly trend. The daily is neutral with its 3-1 and its worth noting 4 out of the last 7 trading sessions have resulted in inside days. I have to assume we are just consolidating before moving lower, but with SPY being slightly bullish going into tomorrow, and FOMC wednesday, it is hard to say for sure which direction we will head in. With this in mind, I am open to playing either side depending on tomorrows session and how the weekly 2-1 plays out.
Honorable mentions:
GOOG and LLY in interesting spots as well. Going to mainly be watching these two and JNJ tomorrow as we prepare for FOMC
Johnson & Johnson Long PositionThe prices close to the support area. We are expecting the price to retest the support and hit our entries at 159.15 and 156.20.
It looks like the price is in the well defined down trend. Therefore, our first target for this long position is at the downsloping resistance and our final target would be at the upper boundary of the range which should be acting as a strong resistance.
JNJ on the beatthe last time i posted was about when it hit the last low of around 152/151.5
just posting an update, seems to be coming back into the buy area, and the next price target would be around 162 if a full run were to happen
$spy on the other hand... still remaining under 400 is scary and fed announcements coming next week, this will determine how the next quarter will project but as it sits right now its not a bad position
JNJ Buy for bounce over $162JNJ is oversold here and near long term support, I'd expect a bounce over $162 in coming days
JNJ new bottom?The Algo's have spoken! RSI, MACD, OBV, all indicate a bottom in JNJ in almost every time frame... could this be a new bottom?
JNJ | I Love It Here | LONGJohnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson BuyHere is my view on JNJ; it is at a support level in a very long uptrend; There is a potential of 15% appreciation if taking profit before the resistance level on cash equity without using leverage.
If using leverage, I'd risk 5% from my trading capital and put a SL below the support area, the Reward to risk will be around 6 to 1 or 30%.
Johnson & Johnson (JNJ) | Inside an Optimal Buying Zone!Hi,
The market has made some pretty good moves up and the current slight correction is bringing prices back to technically good levels and Johnson & Johnson is one of them.
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer goods.
Technically, it has been quite difficult to get it (when there has been such a clear and strong trend, you don't have to be smart to understand that the fundamentals are fine with JNJ), because there have not been such sharp reversals, from which to find a support level and etc, but as you can see from the picture, it has not been impossible. Namely, the price of JNJ has respected a trendline for almost 10 years.
The trend line is drawn from the closing prices (you can do it easily on the line chart) to eliminate the noise and the wicks that the various waves of panic have brought. JNJ has always been bought up very quickly and the growth has been steady.
Also, the price has respected the 50-month moving average (50EMA) almost flawlessly, and at the moment the trend line and the EMA50 form a single punch and are together in one price zone.
Technical criteria for a significant level of support:
1. Trendline, clearly proven in the long term.
2. The Monthly EMA50 has held nicely.
3. The resistance level that worked for three years in 2017-2020, around $150, will start working as a support level.
4. Short-term channel projection
5. Short-term equal waves from the top: AB=CD
The optimal entry point should stay between $147-$160.
Good luck!
NYSE:JNJ 13th FEBRUARY 2023The trendline is the most common part of technical analysis in forex trading. But when compared to support and resistance, trendlines are less commonly used. The trendline should be more significant due to the number of touches.
Trendlines are very suitable in combination with several technical indicators, one of which is the Money Flow Index ( MFI ).
MFI is an indicator used to measure money inflows and outflows from local and foreign investors in the stock. Since MFI measures money inflows and outflows, it also involves volume in its indicator.
In other words, MFI also measures market interest in a stock (inflows and outflows are closely related to market interest). That's why MFI also includes volume in its indicator.
How to read the MFI indicator is very easy, almost the same as how to read other indicators, such as the relative strength index, stochastic, and others.
MFI has 2 main boundary lines, the overbought and oversold lines. The overbought line is at 80 and above. The oversold line is 20 and below (note the arrow above). This means that if the MFI indicator is at 80 and above, there has been too much money inflow from investors, which causes the stock price to rise, thus causing overbought.
Meanwhile, if the MFI indicator is at 20 and below, there is too much money outflow from investors, which causes the stock price to fall, causing oversold.
What to expect this coming week: Dollar, S&P 500, Gold, META, CLThis is my expectations in the market, what I'm looking at in my watchlist and the economic data
Johnson & Johnson – Head and ShouldersBoth macro (lawsuit, bankrupcy denied to mitigate fines) and technical points to downside in the short term. Here we see a head and soulders formation, with downside target coinciding with monthly 100 SME. Strong support for long term hold.
$JNJ with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $JNJ after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 50%.
$JNJ: Heartline Rejection Targeting 38.2%-61.8% RetraceJohnson & Johnson has rejected the Heartline of the Equidistant Channel while showing Bearish Divergence on the MACD and RSI and as a result i now think it will be heading for a minimum .382-.618 Retrace and i will be playing it via monthly put options.
rttghtertrgretgyrr55rythrthtrhthrrthrthyyr56y56y5y445y5y45y5454y54yy455y45yy5y5y5y45y5yrthrththrthrtrhrthrth
JNJ Rising Wedge Break + Fib LevelHas broken to the downside, the initial moves retracement looks to be done, setting up for another leg down.
